Premaitha entered into a secured loan facility agreement with Thermo Fisher, which is secured on the shares of Premaitha's Taiwanese subsidiary, Yourgene Bioscience.
Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.
The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.
Eone-Diagnomics will offer its Gen Screen non-invasive prenatal test in certain Asian markets in partnership with cord blood service provider Cordlife.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.
Increased consumer interest in prenatal health is also spurring use of carrier screening for genetic conditions.
Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.